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Abstract
Calcific uraemic arteriolopathy (CUA) is a rare disease and continues to be a clinical challenge. The typical course of CUA is
characterized by painful skin discolouration and induration evolving to necrotic ulcerations. Medial calcification of cutaneous
arterioles and extensive extracellular matrix remodelling are the hallmarks of CUA. The epidemiology and risk factors
associated with this disease are still not fully understood. Moreover, CUA treatment strategies vary significantly among centres
and expert recommendations are heterogeneous. Registries may provide important insights and information to increase our
knowledge about epidemiology and clinical aspects of CUA andmay help to optimize its therapeutic management. In 2006, we
established an internet-based registry in Germany (www.calciphylaxie.de) to allow online notification of patients with
established or suspected CUA. The registry includes a comprehensive database with questions covering >70 parameters and
items regarding patient-related and laboratory data, clinical background and presentation as well as therapeutic strategies. The
next phase will be to allow international patient registration via www.calciphylaxis.net as part of the multinational EuCalNet
(EuropeanCalciphylaxisNetwork) initiative,which is supported by the ERA-EDTA scientificworking group ‘CKD-MBD’. Based on
the valuable experiencewith the previous GermanCUA registry, EuCalNet will be a useful tool to collect data on the rare disease
CUA and may become a basis for prospective controlled trials in the near future.
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Introduction
Calciphylaxis (calcific uraemic arteriolopathy, CUA) is a rare
disease (Orphanet number ORPHA280062) at the interface of
nephrology, dermatology and cardiovascularmedicine. CUA typ-
ically occurs in chronic dialysis patients and hence nephrologists
aremost likely involved in primary diagnosis and patient care [1].
However, anecdotal reports also exist about cases in patients
without relevant kidney disease (so-called non-uraemic calci-
phylaxis) [2]. Clinically, CUA is characterized by the stepwise de-
velopment of superficial painful sensations and cutaneous
lesions similar to livedo reticularis [3, 4]. Skin necrosis and ulcer-
ation represent the full-blown, ‘late’ clinical picture. Panniculitis
and circumferential calcification of cutaneous arterioles domin-
ate thehistological picture togetherwith endothelial detachment
and luminal occlusion. The prognosis of CUA is extremely poor.
CUA confers a high risk ofmorbidity andmortality, largely result-
ing fromunderlying cardiovascular disease,wound infection and
septicaemia [3]. The aetiology of CUA is still not completely
understood. In most cases, bone and mineral metabolism is al-
tered and may play a significant role in the pathophysiology.
Despite remarkable progress in recent years, evidence-based
therapeutic options are unfortunately absent, since controlled
randomized treatment trials have not yet been undertaken.
What do we know about calciphylaxis?
As with any rare disease, registry studies such as the German
CUA registry (www.calciphylaxie.de) can effectively support cen-
tral data collecting and analysis upon the entire spectrum of the
disease from potential risk factors to good clinical practice. The
German calciphylaxis registry has been actively recruiting pa-
tients since 2006. More than 230 patients have been registered
in the registry up to the beginning of 2015. This impressive num-
ber of patients already provides a rough overview on what is
generally considered ‘good clinical practice’ in the therapeutic
management of these patients (Table 1). In addition, Table 1 sum-
marizes the diversity of the therapeutic actions available. Obvious-
ly, superiority in terms of outcome improvement among these
therapeutical steps cannot be established based on such purely
observational, uncontrolled and sometimes anecdotal data.
Uraemia and uraemia-associated conditions such as distur-
bances in bone and mineral metabolism and inflammation
certainly play a key role as risk factors. We have previously ana-
lysed and reviewed the available literature regarding the clinical
picture, risk factors and outcome in CUA patients [5, 6]. Previous
treatment with vitamin K antagonists (VKA) for oral anticoagula-
tion therapy has been considered as a prominent risk factor [5],
which makes the community speculate about iatrogenic aspects
as part of the pathophysiology cascade [7]. This deserves particu-
lar attention, since previous VKA might represent a potentially
avoidable and modifiable component [5].
What do we not yet know? Why EuCalNet?
Despite the fact that substantial progress in our understanding
about the clinical picture of the disease has been made, signifi-
cant gaps in our knowledge still exist. Systematic personal trans-
fer of CUA patients to specialized research and clinical expert
facilities is virtually impossible facing the overwhelming disease
burden of these patients. Moreover, registry initiativesmay facili-
tate exchange of expertise and stimulate networking between
scientists and clinicians. Accordingly, the consortium members
from ‘EuCalNet’, an international consortium involving clinically
active research partners, have carefully identified a range of
burning questions, the answers of which are not understood or
are still not fully understood (Table 2). In order to overcome
these unmet issues, EuCalNet was founded, which is fully sup-
ported by the ERA-EDTA scientific working group ‘CKD-MBD’.
Those issues (outlined in Table 2) represent major (clinical) re-
search targets and can partly be answered after reaching a critical
mass of patientswith EuCalNet. So EuCalNet is intended to target
unmet medical needs in terms of calciphylaxis.
How is EuCalNet going to be undertaken?
We plan to initiate an internet-based multilingual registry
in which treating physicians will provide anonymous patient
data on:
Table 1. Therapeutic management of CUA patients according to data
extracting from the literature and the German calciphylaxis registry
Modifying dialysis therapy
Increase frequency and duration
Modification of dialysis modality
Switch from peritoneal dialysis to haemodialysis/
haemodiafiltration
Reduction of calcium supply and uptake
Switch to calcium-free phosphate binders
Reduction in calcium concentration in the dialysis bath
Using citrate as the buffer in the dialysis bath
Reduction in active vitamin D dosage
Replacing vitaminK antagonist treatment by heparin or anyother oral
anticoagulation if really needed
Giving vitamin K (unless contraindications are present for one of
these measures)
Therapy against uncontrolled hyperparathyroidism
Give oral calcimimetic
Surgical parathyroidectomy
Optimize CKD-MBD therapy
Efforts to increase adherence to medical therapies
Strengthen anti-calcification properties of serum
Apply sodium thiosulfate
Apply bisphosphonates
Normalizing serum albumin concentration
Parental or intra-dialytic nutrition
Increase oxygen supply to tissue
Treat occluding peripheral arterial disease
Hyperbaric O2 therapy
Give statins
Supportive treatment
Wound care
Pain relief
Antibiotics
Amputation
The efficacy and safety of particular items have not been systematically tested.
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(i) demographics and comorbidities
(ii) the clinical picture including photo documentation and pain
scale reporting
(iii) laboratory data of patients at the time of CUA diagnosis
(iv) concomitant medications
All the above-mentioned data can be repetitively entered, based
on serial follow-up visits. Additionally, a biobank for storage of
serum, plasma and full blood is an integral part of EuCalNet. A
corresponding ethical committee voting will be part of the appli-
cation process. The project partners include the RWTH Aachen
University Hospital as sponsor of the project. Scientific colla-
borators will be acting on behalf of ERA-EDTA scientific working
CKD-MBD (www.era-edta.org/ckdmbd/index.html), which de-
fined calciphylaxis as one of the major future working group-
specific research targets. The sponsor and the collaborators
will coordinate EuCalNet activities in a total of seven European
countries:
(i) Belgium
(ii) France
(iii) Germany
(iv) Italy
(v) Portugal
(vi) Spain
(vii) The Netherlands
What is the aim of EuCalNet?
The international registry will allow identification of more pa-
tients with calciphylaxis than on a national basis alone. Hence,
EuCalNet can contribute to the following issues:
(i) increase awareness of the disease via educational pro-
grammes associated with registry activities
(ii) help establish diagnostic algorithms
(iii) more detailed identification of risk factors
(iv) estimation of overall prognosis and prognosis in subgroups
of patients as well as identification of biomarkers for esti-
mation of prognosis
(v) establishing a biobank for serum, plasma and tissue (skin)
samples as well as autopsy findings
(vi) investigations regarding subgroups of patients
(vii) genotype/phenotype correlations
(viii) description of international state-of-the-art treatment
(ix) regular exchange between experts and treating physicians
about treatment strategies and support treating physicians
with feed back
Methodology of the registry and data
management
Patients diagnosedwith calciphylaxis irrespective of clinical con-
ditions or comorbidities and time of diagnosis (all-comer regis-
try), who are able to provide written and informed consent, can
be included.
Systematic online data collection will be performed similar to
the system already applied at www.calciphylaxie.de. The registry
will be located at www.calciphylaxis.net. Written informed con-
sent will be obtained from each patient in order to allow data and
sample collection for storage in a central databank and biobank;
additionally photo documentation as well as skin and other spe-
cimen will be stored when available. Local ethical approval and
data safety certificateswill be obtained separately in each partici-
pating country.
After online notification via www.calciphylaxis.net, a central
processing of datawill be undertaken on local country-specific le-
vels (first level). Depending on country-specific conditions, the
study centre University Hospital Aachen (second level) will assist
first-level institutions regarding control of completeness and
plausibility of data and also organize expert exchange regarding
confirmation of diagnosis CUA. The primary contact between
treating physician and peripheral centre will be established on
a country level to the local principal investigator (PI). Second-
level data management and final analysis is planned to be per-
formed based on the central databank (see Figure 1). Details re-
garding data management and storage conditions within the
biobank may vary according to local data safety restrictions and
ethical committee voting. In terms of obtaining positive ethical
committee voting, the EuCalNet partners will face divergent
country-specific prerequisites regarding authorization of trial
sites and physicians. For example, some countries will require
such trial site authorization prior to notification of a patient to
the registry.
Interfacing with the ERA-EDTA scientific working group, the
coordinator (PI) of the project will be responsible for overall pro-
ject management to ensure the correct and timely implementa-
tion and overall quality of organization steps and project
maintenance. The PI will serve as the contact point for all part-
ners regarding administrative and financial matters for the dur-
ation of the project. The PI will be responsible for the correct
execution and continuity of the project, online registry data
base set-up and maintenance, preparation of documents (e.g.
registry protocol, patient information and informed consent and
data collection manual) and preparation of documents for notifi-
cation to ethic committees in addition to statistical (interim) ana-
lyses. The role of the investigators and the nature of the registry
are non-interventional (i.e. observational). A systematic testing
of medications, treatment strategies in general or randomization
of patients is not part of the present protocol. In that respect, it
is important to mention again that skin biopsies will not be
performed on a systematic basis but only upon clinical indication
at the discretion of the treating physician. Outcome (mortality)
will be assessed by telephone interview with referring physician
at 6 months after online notification. These interviews will be
performed by local (country-specific) investigators.
Table 2. Burning questions and unsolved issues regarding CUA
Epidemiology
Changes in incidence over time?
Difference in prevalence/incidence in different countries?
Female predominance?
Incidence in different dialysis settings?
Confirmation of diagnosis
Early warning signs and diagnosis of abortive stages?
Procedures to diagnose and optimal diagnostic steps?
Systematic exclusion of differential diagnosis?
How to differentiate from ischaemic lesions?
Risk factors: iatrogenic factors in terms of ‘over-treatment’?
Therapy
Data about therapeutical strategies or most promising treatment
strategies?
Outcome
Change in outcome over time?
Overall mortality?
Different outcome with central versus accrual CUA (predilection
site in the body)?
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Biobank set-up for patients with calciphylaxis
For each patient, the registry initiative aims to collect full blood,
plasma, serum and tissue specimens (the latter where available
via biopsy or surgical resection).
Tissue samples may allow immunohistochemistry and mo-
lecular analysis (e.g. polymerase chain reaction) with special
focus on factors indicative for extracellular matrix remodelling
and soft tissue calcification [8].
Definition of end points and objectives
The primary objective of the EuCalNet registry is to describe
the prognosis of patients with calciphylaxis. Therefore, the
primary end point is survival time defined as (i) time between
diagnosis of calciphylaxis and death (or end of follow-up) or
(ii) in cases where time of diagnosis is not recorded, time be-
tween registry recording and death (or end of follow-up). Sec-
ondary objectives of the EuCalNet initiative are summarized
in Table 3.
Financial support for EuCalNet
The EuCalNet project is an integral part of the work package of
the ERA-EDTA scientific working group CKD-MBD and this close
collaboration has led to a strong overlap between EuCalNet con-
sortium partners and working group board members. Financial
support is provided by Amgen and Sanofi.
Potential health impact of a European registry
initiative
The above-mentioned multicentre and multinational approach
may be particularly valuable due to the following reasons:
(i) The prognosis of patients with CUA is devastating and data
collection within a transnational project helps establishing
data upon good clinical practice that in the future may be
the basis for randomized prospective trials.
(ii) Amultinational approachmayhelp elaborating geographical
differences in terms of incidence, clinical picture, therapy
and outcome.
(iii) Creation of a central large-scale biobank permits future ana-
lysis of novel potentially interesting pathophysiological
pathways.
(iv) CUA may serve as a high-speed template for other forms of
extra-osseous calcification in CKD-MBD. Therefore, data
Fig. 1. Local study centres collect and administrate cases from their country. A central study centre reviews and consolidates all collected data.
Table 3. Secondary objectives of EuCalNet
Secondary objectives
Increase awareness and facilitate diagnosis of calciphylaxis
Description of state-of-the-art treatment strategies
The identification of subgroups of patients with potentially distinct
patterns of risk factors, clinical picture and prognosis
Annual symposia and publications about calciphylaxis based on
the EuCalNet registry work
Networking among experts
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regarding the pathogenesis of CUA may add additional in-
sights into (non-uraemic) calcifying arteriosclerosis and
atherosclerosis.
The EuCalNet registry and international
cooperations
The EuCalNet initiativewill continuewith previously established
cooperations between the German calciphylaxis registry and
international partners. Prospective calciphylaxis registries are
recruiting patients also in the UK (UK Calciphylaxis Study)
(http://www.gmann.co.uk/website/trials/iccn/home.cfm) and in
Australia (Australian Calciphylaxis Registry) (http://www.calci
phylaxis.org.au). Those cooperations have been particularly
fruitful in the past in terms of expert exchange about, for ex-
ample, IT solutions,marketing strategies and clinical data collec-
tion. Prerequisites in terms of, for example, successful ethical
approval regarding data collection and handling in such regis-
tries vary substantially between countries and in this respect,
EuCalNet initiation will continuously benefit from exchange of
knowledge between currently recruiting CUA registries. Merging
clinical expertise between these cooperating registry initiatives is
a fruitful stimulus for future scientific publications [5].
Summary
Understanding the aetiology of CUA remains to be an important
challenge. The initiation of a multinational registry EuCalNet is
an importantfirst step.Unfortunately, evidence-based therapeutic
options are absent, since controlled treatment trials have not yet
been undertaken. The undertaking of such a trial is currently
being extensively discussed among experts.
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